News & Updates

Show Multimedia Only

DOACs heighten stroke, reduce MI risks in patients with AF-MS

18 Aug 2026

Use of direct oral anticoagulants (DOACs) vs warfarin appears to increase the 1-year risk for stroke but lower the risk for myocardial infarction (MI) in Asian patients with atrial fibrillation (AF) and mitral stenosis (MS), according to a study.

DOACs heighten stroke, reduce MI risks in patients with AF-MS

18 Aug 2026

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

18 Aug 2026

Hypertension and diabetes in midlife have been associated with increased risk of early-onset dementia, specifically the non-Alzheimer’s type, in a population-based case-control study.

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

18 Aug 2026

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

17 Aug 2026 by

Gefurulimab, a novel bispecific nanobody that targets complement factor 5 (C5) delivers rapid and sustained clinical benefit in patients with anti–acetylcholine receptor antibody–positive (AChR-Ab+) generalized myasthenia gravis (gMG), as shown in the phase III PREVAIL trial.

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

17 Aug 2026

Tech-blended exercise a feasible strategy for improving outcomes in T2D

16 Aug 2026 by

A 12-week exercise intervention delivered via a blended modality of face-to-face, Zoom-based, and video-recorded sessions to promote adherence to physical activity among middle-aged and older adults with type 2 diabetes (T2D) in Singapore is feasible and may help improve outcomes, including cognitive performance, as shown in a mixed-methods study.

Tech-blended exercise a feasible strategy for improving outcomes in T2D

16 Aug 2026

Rivaroxaban superior to metoprolol for migraine in patients with PFO

11 Aug 2026 by

Three antithrombotic medications (aspirin, clopidogrel, and rivaroxaban) demonstrate noninferiority to metoprolol for responder rate (RR) in patients with migraine and patent foramen ovale (PFO), a study has shown. Rivaroxaban also delivers the highest RR without increasing major bleeding events.

Rivaroxaban superior to metoprolol for migraine in patients with PFO

11 Aug 2026

A leap forward towards more precise and individualized immunotherapy for glioblastoma

11 Aug 2026 by

Researchers from the Clinical Neuroscience Consortium (CNC), a collaborative platform jointly established by the University of Hong Kong (HKU) and Queen Mary Hospital in collaboration with the Hong Kong Genome Institute (HKGI), have achieved a major breakthrough in brain cancer research, uncovering thousands of previously unannotated isoforms and identifying potential targets for both precision therapeutics and personalized cancer vaccines.

A leap forward towards more precise and individualized immunotherapy for glioblastoma

11 Aug 2026

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

10 Aug 2026 by

Treatment with the oral orexin receptor 2 (OX2R) agonist oveporexton improves symptom control, daily function, and cognitive outcomes in patients with narcolepsy type 1, according to pooled data from two phase III studies, The First Light and The Radiant Light.

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

10 Aug 2026

Inhaled levodopa helps manage off episodes in PD, regardless of age

09 Aug 2026 by

Treatment with the inhaled levodopa formulation CVT-301 provides rapid motor symptom relief during off periods, with consistent efficacy seen across Parkinson’s disease (PD) patients of all ages, according to a post hoc analysis of three phase III trials.

Inhaled levodopa helps manage off episodes in PD, regardless of age

09 Aug 2026

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026 by

In the phase II CELIA trial, the investigational tau-targeting antisense oligonucleotide (ASO) diranersen has shown therapeutic potential in patients with early Alzheimer’s disease (AD), yielding substantial reductions in tau burden and slowing clinical decline despite missing its primary endpoint.

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026

High outdoor heat detrimental to individuals with dementia

07 Aug 2026 by

A study presented at AAIC 2026 shows that short-term exposure to outdoor heat may exacerbate behavioural and psychological symptoms of dementia (BPSD), including affective and psychotic manifestations.

High outdoor heat detrimental to individuals with dementia

07 Aug 2026

News & Updates

Showing Neurology articles

Showing

Specialty:

DOACs heighten stroke, reduce MI risks in patients with AF-MS

DOACs heighten stroke, reduce MI risks in patients with AF-MS

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

Tech-blended exercise a feasible strategy for improving outcomes in T2D

Tech-blended exercise a feasible strategy for improving outcomes in T2D

Rivaroxaban superior to metoprolol for migraine in patients with PFO

Rivaroxaban superior to metoprolol for migraine in patients with PFO

A leap forward towards more precise and individualized immunotherapy for glioblastoma

A leap forward towards more precise and individualized immunotherapy for glioblastoma

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

Oveporexton confers symptomatic, functional, cognitive benefits in narcolepsy type 1

Inhaled levodopa helps manage off episodes in PD, regardless of age

Inhaled levodopa helps manage off episodes in PD, regardless of age

Tau-targeting therapy for early AD gets a pass to phase III

Tau-targeting therapy for early AD gets a pass to phase III

High outdoor heat detrimental to individuals with dementia

High outdoor heat detrimental to individuals with dementia